Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Juniper Pharmaceuticals
Following its decision to maintain a stock listing for SillaJen earlier this month, the Korea Exchange has done the same for Kolon TissueGene, which had faced delisting but has resumed trading amid decisive moves to improve its business.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- Topical Delivery
- Drug Delivery
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.
- Juniper Pharma Services
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.